Articles tagged "Renal function"

2018 American Transplant Congress
Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection – A Double-Blind Randomized Placebo-Controlled Trial (BORTEJECT Study)
F. Eskandary,¹ H. Regele,² G. Bond,¹ N. Kozakowski,² M. Wahrmann,¹ L. Hidalgo,³ H. Haslacher,⁴ C. Kaltenecker,¹ M-.B. Aretin,⁵ R. Oberbauer,¹ J. Reeve,⁶ P. Halloran,⁶ G. Böhmig.¹
¹Nephrology and Dialysis, Medical University Vienna, Viena, Austria; ²Institute of Clinical Pathology, Medical University Vienna, Vienna, Austria; ³Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada; ⁴Department of Laboratory Medicine, Medical University Vienna, Vienna, Austria; ⁵Pharmacy Department, General Hospital Vienna, AKH, Vienna, Austria; ⁶Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, AB, Canada.
Background. Antibody-mediated rejection (ABMR) is a leading cause of long-term kidney transplant loss. Optimal treatment of late ABMR is unclear, and our current knowledge is…
2018 American Transplant Congress
Once-Daily MeltDose Tacrolimus Formulation and Renal Function in Caucasian Fast Tacrolimus Metabolizers: Does Early Identification Have an Impact in PK Sensitive Patients?
K. Budde,⁶ B. Suwelack,¹ D. Stevens,³ W. Du,⁴ C. Procaccianti,⁵ C. Maas,⁵ S. Bunnapradist.²
¹University Hospital of Münster, Münster, Germany; ²David Geffen School of Medicine at UCLA, Los Angeles; ³Veloxis Pharmaceuticals, Cary; ⁴Clinical Statistics Consulting, Norrystown; ⁵Chiesi Farmaceutici S.p.A., Parma, Italy; ⁶Charité Universitatsmedizin, Berlin, Germany.
Tacrolimus (TAC) nephrotoxicity can be seen even at low blood trough levels, with factors beyond trough levels potentially contributing. TAC fast metabolizers have higher Cmax,…
2018 American Transplant Congress
Renal and Bone Safety in Post Liver Transplant Patients with Chronic Kidney Disease Receiving Tenofovir Alafenamide for HBV Prophylaxis
E. Gane,¹ B. George,¹ S. Munn,¹ H. Wang,² V. Suri,² A. Gaggar.²
¹Auckland City Hospital, Auckland, New Zealand; ²Gilead Sciences, Foster City, CA.
Background and Aims: Chronic Hepatitis B (CHB) remains a leading indication for orthotopic liver transplantation (OLT) globally. Common complications following OLT include renal dysfunction secondary…
2018 American Transplant Congress
Robotic Assisted Live Donor Kidney Transplantation – Technique and Outcomes
H. Pahari,¹ B. Waldman,² J. Stracke,¹ L. Malinzak,¹ J. Denny,¹ D. Kim,¹ W. Jeong,³ M. Menon,³ A. Yoshida.¹
¹Transplant Surgery, Henry Ford Hospital, Detroit, MI; ²Wayne State University, Detroit, MI; ³Urology, Henry Ford Hospital, Detroit, MI.
Background: Robotic assisted kidney transplantation (RAKT) is now a feasible minimally invasive option in place of open living donor kidney transplant (OKT). Here, we briefly…
2018 American Transplant Congress
Long-Term Outcomes of a Steroid-Free, Belatacept-Based Immunosuppressive Regimen Plus Sirolimus Using Alentuzumab Induction in Renal Transplantation
A. Guasch,¹ A. Ghali,¹ S. Mead,¹ A. Mehta,¹ H. Xu,² A. Kirk.²
¹Emory Transplant Center, Emory University, Atlanta, GA; ²Dept of Surgery, Duke University, Durham, NC.
The toxicities of CNIs and steroids have a negative impact on kidney transplantation. Belatacept is a safe, non-nephrotoxic alternative to CNIs, that may lead to…
2018 American Transplant Congress
Novel Vascular Inflow Offers Renal Transplantation to Recipients with Severe Central and Peripheral Vascular Disease
S. Mao,¹ E. Giorgakis,² A. Moss,² T. Taner.¹
¹William J. von Liebig Center for Transplantation, Mayo Clinic, Rochester, MN; ²Transplantation Surgery, Mayo Clinic, Phoenix, AZ.
Background: Absence of suitable implant locations for donor renal vessels may be a major problem in patients with significant central and peripheral vascular disease. We…
2018 American Transplant Congress
Prolonged-Release Tacrolimus Dosing in De Novo Kidney Transplantation: Randomized, Open-Label, Pilot Study
Y. Kim,¹ Y. Chiang,² S. Kim,³ M. Kim,⁴ S. Park,⁵ S. Wu,⁶ K. Horita,⁷ Y. Nakashima,⁷ H. Jiang,⁸ D. Han.¹
¹Asan Medical Center, Seoul, Korea; ²Chang Gung Memorial Hospital-Linkou, Taoyuan City, Taiwan; ³Samsung Medical Center, Seoul, Korea; ⁴Severance Hospital, Seoul, Korea; ⁵Dongsan Medical Center, Daegu, Korea; ⁶Tri-Service General Hospital, Taipei City, Taiwan; ⁷Astellas Pharma, Inc., Tokyo, Japan; ⁸Astellas Pharma, Inc., Maao, Singapore.
A multicenter, randomized, open-label, parallel-group, pilot, 52-wk study in Asian countries that assessed renal function, efficacy, and safety of low vs standard-dose prolonged-release tacrolimus (PRT)…
2018 American Transplant Congress
Everolimus with Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplant Recipients: Efficacy and Safety Outcomes from the TRANSFORM Study
S. Mulgaonkar,¹ J. Pascual,¹ S. Chadban,¹ H. Tedesco,¹ S. Berger,¹ Y. Qazi,¹ C. Legendre,¹ N. Basic-Jukic,¹ P. Bernhardt,² F. Vincenti.¹
¹TRANSFORM Study Group, Livingston; ²Novartis Pharma AG, Basel, Switzerland.
Purpose: Everolimus (EVR)-facilitated calcineurin inhibitor (CNI) reduction regimens help prevent long-term CNI nephrotoxicity in kidney transplant recipients (KTxRs). TRANSFORM (NCT01950819) is the largest study in…
2018 American Transplant Congress
Estimated GFR for Living Kidney Donor Evaluation before and after Donor Nephrectomy
Y. Kakuta,¹ M. Okumi,¹ R. Imamura,² N. Ichimaru,² S. Takahara,² H. Ishida,¹ K. Tanabe.¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan; ²Urology, Osaka Graduate School of Medicine, Suita, Osaka, Japan.
BackgroundKidney transplantation from living donors is an important treatment for patients with kidney failure. An accurate evaluation of renal function must be conducted before and…
2018 American Transplant Congress
Superior Renal Function with CNI-Free Everolimus over Standard CNI-Based Regimen: 18 Months Data from the Randomized, Multi-Center MANDELA Trial in De Novo Heart Transplant Recipients
M. J. Barten,¹ S. W. Hirt,¹ J. Garbade,¹ C. Bara,¹ A. Doesch,¹ C. Knosalla,¹ C. Grinninger,¹ J. Stypmann,¹ C. Sieder,² M. Junge,² U. Schulz.¹
¹Mandela Study Group, Germany; ²Novartis, Pharma, Germany.
Purpose: The MANDELA study (NCT00862979) was designed to assess the benefit on renal function of either CNI-free or CNI-minimized EVR-based regimen after early conversion of…